Lipid nanoparticles outperform electroporation in mRNA-based CAR T cell engineering
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The frequently postulated “better cell fitness” of LNP-transfected T cells has typically been supported only by viability data,45 with limited mechanistic insight.”
From Lipid nanoparticle mRNA delivery preserves CAR T cell cytotoxicity and limits exhaustion compared to electroporation (2026) · cites this paper as [45]
In the citing paper
“The choice of IVT mRNA delivery method critically influences CAR expression kinetics and therapeutic potential.45”
From Lipid nanoparticle mRNA delivery preserves CAR T cell cytotoxicity and limits exhaustion compared to electroporation (2026) · cites this paper as [45]
In the citing paper
“Alternatively, lipid nanoparticles (LNPs) have emerged as an ex vivo mRNA delivery platform.31,44,45”
From Lipid nanoparticle mRNA delivery preserves CAR T cell cytotoxicity and limits exhaustion compared to electroporation (2026) · cites this paper as [45]
In the citing paper
“LNP-mediated mRNA delivery offers several practical advantages in the ex vivo setting, including reduced cellular stress, preserved functional fitness,28,44,45,46,47 single-step multiplexing capability, and scalability.”
From Lipid nanoparticle mRNA delivery preserves CAR T cell cytotoxicity and limits exhaustion compared to electroporation (2026) · cites this paper as [45]
In the citing paper
“This interpretation is consistent with reports indicating that electroporation may produce a more rapid onset of CAR expression, whereas LNP delivery results in more gradual yet sustained expression.24”
From Human T cell engineering via serial delivery of mRNA encapsulated within lipid nanoparticles (2026) · cites this paper as [24]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Car t cell immunotherapy for human cancer
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207
Long, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3838 · Cited by 1,815
Fraietta, J. A., Lacey, S. F., Orlando, E. J., Pruteanu-Malinici, I., Gohil, M., Lundh, S., Boesteanu, A. C., Wang, Y., O’Connor, R. S., Hwang, W.-T., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0010-1 · Cited by 1,785
CAR T cells produced in vivo to treat cardiac injury
Rurik, J. G., Tombácz, I., Yadegari, A., Méndez Fernández, P. O., Shewale, S. V., Li, L., Kimura, T., Soliman, O. Y., Papp, T. E., Tam, Y. K., et al. (2022) · Science · doi:10.1126/science.abm0594 · Cited by 1,400
Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms
Akinc, A., Querbes, W., De, S., Qin, J., Frank-Kamenetsky, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Cantley, W. L., Dorkin, J. R., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.85 · Cited by 1,261
Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells
Fraietta, J. A., Nobles, C. L., Sammons, M. A., Lundh, S., Carty, S. A., Reich, T. J., Cogdill, A. P., Morrissette, J. J. D., DeNizio, J. E., Reddy, S., et al. (2018) · Nature · doi:10.1038/s41586-018-0178-z · Cited by 862
Recent advances and discoveries in the mechanisms and functions of CAR T cells
Larson, R. C., & Maus, M. V. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00323-z · Cited by 852
Andries, O., Mc Cafferty, S., De Smedt, S. C., Weiss, R., Sanders, N. N., & Kitada, T. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.051 · Cited by 701
Kloss, C. C., Lee, J., Zhang, A., Chen, F., Melenhorst, J. J., Lacey, S. F., Maus, M. V., Fraietta, J. A., Zhao, Y., & June, C. H. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.003 · Cited by 648
Research works printed but not linked: 37
- Watanabe, 2022, Impact of Manufacturing Procedures on CAR T Cell Functionality, Front. Immunol., 13, 10.3389/fimmu.2022.876339 · DOI · Paper page
- Melenhorst, 2022, Decade-long leukaemia remissions with persistence of CD4+ CAR T cells, Nature, 602, 503, 10.1038/s41586-021-04390-6 · DOI · Paper page
- Miliotou, 2018, CAR T-cell Therapy: A New Era in Cancer Immunotherapy, Curr. Pharmaceut. Biotechnol., 19, 5, 10.2174/1389201019666180418095526 · DOI · Paper page
- Wat, 2022, Hypogammaglobulinemia After Chimeric Antigen Receptor (CAR) T-Cell Therapy: Characteristics, Management, and Future Directions, J. Allergy Clin. Immunol. Pract., 10, 460, 10.1016/j.jaip.2021.10.037 · DOI
- Vora, 2020, Infectious Complications Following CD19 Chimeric Antigen Receptor T-cell Therapy for Children, Adolescents, and Young Adults, Open Forum Infect. Dis., 7, ofaa121, 10.1093/ofid/ofaa121 · DOI
- Irving, 2021, Choosing the Right Tool for Genetic Engineering: Clinical Lessons from Chimeric Antigen Receptor-T Cells, Hum. Gene Ther., 32, 1044, 10.1089/hum.2021.173 · DOI · Paper page
- Moretti, 2022, The Past, Present, and Future of Non-Viral CAR T Cells, Front. Immunol., 13, 867013, 10.3389/fimmu.2022.867013 · DOI
- Miliotou, 2020, In Vitro-Transcribed (IVT)-mRNA CAR Therapy Development, Methods Mol. Biol., 2086, 87, 10.1007/978-1-0716-0146-4_7 · DOI
- Soundara Rajan, 2020, In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update, Int. J. Mol. Sci., 21, 6514, 10.3390/ijms21186514 · DOI · Paper page
- Beatty, 2014, Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies, Cancer Immunol. Res., 2, 112, 10.1158/2326-6066.CIR-13-0170 · DOI · Paper page
- Beatty, 2018, Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial, Gastroenterology, 155, 29, 10.1053/j.gastro.2018.03.029 · DOI · Paper page
- Cummins, 2017, Treating Relapsed/Refractory (RR) AML with Biodegradable Anti-CD123 CAR Modified T Cells, Blood, 130, 1359
- Tchou, 2017, Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer, Cancer Immunol. Res., 5, 1152, 10.1158/2326-6066.CIR-17-0189 · DOI · Paper page
- Svoboda, 2018, Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma, Blood, 132, 1022, 10.1182/blood-2018-03-837609 · DOI · Paper page
- Shah, 2023, Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T cells Administered Intravenously in Patients with Melanoma & Breast Carcinoma, Cancer Res. Commun., 3, 821, 10.1158/2767-9764.CRC-22-0486 · DOI
- Shi, 2018, A Review on Electroporation-Based Intracellular Delivery, Molecules, 23, 3044, 10.3390/molecules23113044 · DOI · Paper page
- DiTommaso, 2018, Cell engineering with microfluidic squeezing preserves functionality of primary immune cells in vivo, Proc. Natl. Acad. Sci. USA, 115, E10907, 10.1073/pnas.1809671115 · DOI · Paper page
- Xin, 2022, In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy, Front. Oncol., 12, 10.3389/fonc.2022.809754 · DOI · Paper page
- Parayath, 2020, In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo, Nat. Commun., 11, 6080, 10.1038/s41467-020-19486-2 · DOI · Paper page
- Ye, 2022, Research advance in lipid nanoparticle-mRNA delivery system and its application in CAR-T cell therapy. Zhejiang da xue xue bao, Medical sciences, 51, 185
- Kitchen, 2004, CD4 on CD8(+) T cells directly enhances effector function and is a target for HIV infection, Proc. Natl. Acad. Sci. USA, 101, 8727, 10.1073/pnas.0401500101 · DOI
- Moradian, 2022, Chemical modification of uridine modulates mRNA-mediated proinflammatory and antiviral response in primary human macrophages. Molecular therapy, Nucleic acids, 27, 854, 10.1016/j.omtn.2022.01.004 · DOI · Paper page
- Parr, 2020, N 1-Methylpseudouridine substitution enhances the performance of synthetic mRNA switches in cells, Nucleic Acids Res., 48, e35, 10.1093/nar/gkaa070 · DOI · Paper page
- Billingsley, 2022, Orthogonal Design of Experiments for Optimization of Lipid Nanoparticles for mRNA Engineering of CAR T Cells, Nano Lett., 22, 533, 10.1021/acs.nanolett.1c02503 · DOI · Paper page
- Billingsley, 2020, Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering, Nano Lett., 20, 1578, 10.1021/acs.nanolett.9b04246 · DOI · Paper page
- Tanaka, 2021, Improvement of mRNA Delivery Efficiency to a T Cell Line by Modulating PEG-Lipid Content and Phospholipid Components of Lipid Nanoparticles, Pharmaceutics, 13, 2097, 10.3390/pharmaceutics13122097 · DOI
- Birkholz, 2009, Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer, Gene Ther., 16, 596, 10.1038/gt.2008.189 · DOI
- von Auw, 2023, U.S. Comparison of two lab-scale protocols for enhanced mRNA-based CAR-T cell generation and functionality, Sci. Rep., 13, 18160, 10.1038/s41598-023-45197-x · DOI
- Inoo, 2016, Immunological quality and performance of tumor vessel-targeting CAR-T cells prepared by mRNA-EP for clinical research, Mol. Ther. Oncolytics, 3, 10.1038/mto.2016.24 · DOI
- Harris, 2021, Optimization of electroporation and other non-viral gene delivery strategies for T cells, Biotechnol. Prog., 37, 10.1002/btpr.3066 · DOI
- Campillo-Davo, 2021, The Ins and Outs of Messenger RNA Electroporation for Physical Gene Delivery in Immune Cell-Based Therapy, Pharmaceutics, 13, 396, 10.3390/pharmaceutics13030396 · DOI
- Paramasivam, 2022, Endosomal escape of delivered mRNA from endosomal recycling tubules visualized at the nanoscale, J. Cell Biol., 221, 10.1083/jcb.202110137 · DOI · Paper page
- Thomas, 2018, Microfluidic Production and Application of Lipid Nanoparticles for Nucleic Acid Transfection, Methods Mol. Biol., 1792, 193, 10.1007/978-1-4939-7865-6_14 · DOI
- Paunovska, 2022, The Extent to Which Lipid Nanoparticles Require Apolipoprotein E and Low-Density Lipoprotein Receptor for Delivery Changes with Ionizable Lipid Structure, Nano Lett., 22, 10025, 10.1021/acs.nanolett.2c03741 · DOI
- Zhang, 2021, Helper lipid structure influences protein adsorption and delivery of lipid nanoparticles to spleen and liver, Biomater. Sci., 9, 1449, 10.1039/D0BM01609H · DOI · Paper page
- Gomes-Silva, 2017, Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent, Cell Rep., 21, 17, 10.1016/j.celrep.2017.09.015 · DOI · Paper page
- Webb, 2022, Current Status and Future Perspectives on MRNA Drug Manufacturing, Mol. Pharm., 19, 1047, 10.1021/acs.molpharmaceut.2c00010 · DOI
Cited by
Picht, S., Farrera-Sal, M., Hiller, A. L., Brumhard, S., Klaas, A. M., Schulenberg, S., Friedrich, R., Scholz, C., Hemmerling, L., Simon, D. N., et al. (2026) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2026.102929 · Cited by 7
Human T cell engineering via serial delivery of mRNA encapsulated within lipid nanoparticles
Ramamurthy, A., Scimonelli, G., Murphy, W. L., & Saha, K. (2026) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2026.103081
Metadata
- Authors
- Kitte, R., Rabel, M., Geczy, R., Park, S., Fricke, S., Koehl, U., & Tretbar, U. S.
- Venue
- Molecular Therapy Methods & Clinical Development
- Publisher
- Elsevier BV
- Published
- 2023-12
- Volume
- 31
- Pages
- 101139
- ISSN
- 2329-0501
- Cited by
- 125
- References
- 11
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Funders
- Bundesministerium für Bildung und Forschung (16GW0322)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lipid nanoparticles outperform electroporation in mRNA-based CAR T cell engineering. https://app.cochat.ai/papers/10.1016/j.omtm.2023.101139
- The paper
- Kitte, R., Rabel, M., Geczy, R., Park, S., Fricke, S., Koehl, U., & Tretbar, U. S. (2023). Lipid nanoparticles outperform electroporation in mRNA-based CAR T cell engineering. Molecular Therapy Methods & Clinical Development. https://doi.org/10.1016/j.omtm.2023.101139
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.